Excellent posts SSV, FB and GSW. I think that the important distinction to make here is that SBN is first and foremost a biomedical technology company- it also just happens to have a suite of fully developed commercial products right now to sweeten the mix!
Whilst revenues are always important for most companies, the critically valuable component for SBN in the near term will be its IP. This will be the driver of future revenues through extended R&D programs. As for establishing a footprint in China complete with monopoly,that is the sort of blue sky potential that you can only dream of with small cap stocks. I am very pleased to say that in the case of SBN, when regulatory approval is eventually given the green light in China,it will become the precursor for the analysis of amazing revenue potential. Given the size of the market,its needs and the power and influence of a centrally controlled Govt structure that mandates and determines policies that are then carried out by all affiliated Govt agents and authorities throughout the country,it is potentially massive and just the thought of the likely outcome for a $0.014 stock listed on the ASX atm is simply overwhelming, even with out turning one single dollar.
Only my thoughts although and I would never suggest as both FB and GSW have posted that revenue models will not ultimately be the driver medium term here but for me and the short term, it is just the real and brutal potential of what could be!!!
Cheers
SBN Price at posting:
0.8¢ Sentiment: ST Buy Disclosure: Held
